Search

Displaying all 4 results
DrugBest match

Ticagrelor

go.drugbank.com/drugs/DB08816
ApprovedInvestigational

Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y12 receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU, . Ticagrelor was granted EMA appr...

  1. Drug

    Cinacalcet

    go.drugbank.com/drugs/DB01012
    ApprovedInvestigational

    Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.

    Products: TICAGRELOR EG, TICAGRELOR KRKA
  2. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset

  3. Drug

    Bentracimab

    go.drugbank.com/drugs/DB16659
    Investigational

    Bentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or